stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Free cash flow margin
HUTCHMED (China) Limited Sponsored ADR's free cash flow margin over the twelve months to 30 June 2026 was 0.00%, up 16.2 percentage points from fiscal 2025 (−16.2%). Over the past ten years it has ranged from −71.6% (fiscal 2022) to 22.3% (fiscal 2023); the current reading is higher than 55% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −16.2% | (13.42) |
| FY2024 | −2.77% | (25.04) |
| FY2023 | 22.3% | 93.86 |
| FY2022 | −71.6% | (9.54) |
| FY2021 | −62.1% | (26.24) |
| FY2020 | −35.8% | 7.86 |
| FY2019 | −43.7% | (25.36) |
| FY2018 | −18.3% | (12.52) |
| FY2017 | −5.79% | 0.64 |
| FY2016 | −6.43% | 0.70 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 38.1% |
| TRLV Trulieve Cannabis Corp. compare | 22.4% |
| XERS Xeris Biopharma Holdings, Inc. compare | 20.0% |
| ANIP ANI Pharmaceuticals, Inc. compare | 19.7% |
| PBH Prestige Consumer Healthcare Inc. compare | 18.4% |
| PRGO Perrigo Company plc compare | 4.11% |
| HCM HUTCHMED (China) Limited Sponsored ADR | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement